Uva-Ursi: The Urinary Herb With Two Unfavourable Trials

By Femipros TeamLast updated October 29, 202610 min readFemipro reading room · Reviewed by Dr. Jennifer Roelands, MD

A herb with a long reputation

Bearberry, Arctostaphylos uva-ursi, is one of the oldest urinary remedies in the European herbal tradition. It appears in monographs across Europe, it is sold on its own in most pharmacies, and it turns up in a large fraction of the urinary blends on the market, including the one sold on this website.

Traditional use is not nothing. It is a reason to investigate something rather than a reason to believe it, and the FTC is explicit that traditional-use claims either need scientific backing or need to be qualified clearly as lacking it.

Uva-ursi has been investigated. Twice, properly, in randomised controlled trials in women with urinary tract infection. This post is about what those trials found, because the answer is not what the reputation would lead you to expect and it is almost never mentioned on a page selling the stuff.

What arbutin actually does

The active constituent is arbutin, a glycoside. Swallowed, it is absorbed, metabolised and excreted into urine largely as hydroquinone and its conjugates. Hydroquinone has antimicrobial properties, and the proposed mechanism is that it reaches the urinary tract in the urine itself rather than acting systemically.

The pharmacokinetics are established rather than theoretical. A crossover study in 16 healthy volunteers recovered about 65 percent of an administered arbutin dose in urine as hydroquinone equivalents, comprising free hydroquinone plus glucuronide and sulfate conjugates, with substantial variation between individuals.

So the mechanism is real and measurable. That is more than several ingredients in this aisle can say. What it does not establish is that it helps, which is what the trials were for.

REGATTA: more kidney infections, not fewer

The REGATTA trial randomised 398 women with uncomplicated urinary tract infection in primary care to either uva-ursi extract or fosfomycin, a single-dose antibiotic. It was designed to test whether the herb could reduce antibiotic use without making patients worse.

The first half worked. Uva-ursi cut antibiotic courses by 63.6 percent, which in an era of antimicrobial resistance is a genuinely worthwhile thing to achieve.

The second half did not. Uva-ursi failed non-inferiority for symptom burden, coming in at 136.5 percent of the control group: women on the herb felt worse, for longer. And there were more cases of pyelonephritis, infection that has ascended to the kidney, in the uva-ursi arm: eight against two. The authors concluded that uva-ursi led to a higher symptom burden and more safety concerns than fosfomycin.

Eight against two is a small number of events and the difference should not be over-interpreted from a single trial. It is also exactly the direction nobody wanted, in the outcome that matters most, and it is the sort of finding that does not appear in marketing copy.

ATAFUTI: no benefit at all

The ATAFUTI trial randomised 382 women in a factorial design testing uva-ursi extract and ibuprofen as alternatives to immediate antibiotics.

The uva-ursi arm showed no evidence of benefit on frequency symptoms: a difference of −0.06 with a confidence interval from −0.33 to 0.21, which is as close to nothing as a trial result gets. It produced no significant reduction in antibiotic use either, with an odds ratio of 0.59 and an interval from 0.22 to 1.58. The only arm that reduced antibiotic consumption was the ibuprofen one.

Where the short-course rule comes from

Every serious monograph on uva-ursi limits how long a course should run, typically to a week or so and to a handful of courses a year. That limit does not come from the trials above. It comes from the chemistry in the second section.

If roughly 65 percent of an arbutin dose appears in urine as hydroquinone equivalents, then a person taking it daily has continuous hydroquinone exposure. Hydroquinone is not something anyone wants indefinite exposure to, and the traditional limit is a precautionary response to that rather than to any specific observed harm.

This matters far more for a daily supplement than for a herbal course. A traditional preparation is taken for a week when symptoms appear. A capsule containing uva-ursi is sold as a once-daily product, often in six-bottle packs covering 180 days. Those are different exposure patterns, and the second one has never been assessed by anybody.

The risk assessment, and who wrote it

There is a published risk assessment on this exact question, and it is reassuring. de Arriba and colleagues estimated that a therapeutic daily dose, 420 mg of hydroquinone derivatives as anhydrous arbutin, produces free-hydroquinone urinary exposure of about 11 micrograms per kilogram of body weight per day, well below a derived permitted exposure of 100. They found no direct human evidence of liver toxicity, kidney toxicity or tumour promotion.

Two things should be said next to it every time it is cited, and this website says them every time.

First, all three authors were employed by a bearberry product manufacturer. That does not make the analysis wrong, and it is a perfectly ordinary situation in toxicology, where the people with the data are often the people with the product. It does make it interested testimony, and a reader is entitled to know without having to check the affiliations themselves.

Second, and more importantly, the assessment addresses short-term recommended use. It is not an assessment of taking uva-ursi daily for six months, which is what a six-bottle supplement order amounts to. Nobody has assessed that.

The one finding that was genuinely good

It would be unbalanced to leave REGATTA as purely a bad news story, because one of its findings was a real success and is the reason the trial was run at all.

Uva-ursi cut antibiotic courses by 63.6 percent. In a trial designed around antimicrobial stewardship, that is the primary thing you are hoping to see. Most uncomplicated urinary tract infections in otherwise healthy women resolve without an antibiotic, and every course avoided is a small contribution to slowing resistance. A herb that lets two thirds of patients skip one has done something.

The trouble is what it cost. Those women had a higher symptom burden, meaning they felt worse for longer, and there were more cases of infection reaching the kidney. So the honest summary of REGATTA is not “uva-ursi does not work”. It is that uva-ursi reduced antibiotic use at the price of a worse patient experience and a safety signal, and the authors judged that trade unacceptable.

It is worth noticing that the ATAFUTI trial found something similar from the other direction. Its uva-ursi arm produced no benefit, and the arm that did reduce antibiotic consumption was ibuprofen. Simple analgesia, not a urinary herb, was what helped people wait an infection out.

None of this transfers cleanly to a daily supplement, and that is the point worth carrying away. Both trials gave therapeutic doses to women with an active infection. A supplement gives an unstated fraction of a blend to somebody who is well. Those are different questions, and the trials answer the first one rather than the second. What they do establish is that uva-ursi is a pharmacologically active herb with a real adverse signal, not a harmless traditional tonic with nothing but upside, and that is the frame to bring to any label containing it.

What this means for a blend containing it

Most products do not contain a therapeutic dose of uva-ursi. They contain some, inside a blend, usually with the individual amount unpublished. The product sold on this website is exactly that case: bearberry leaf sits inside a 350 mg herbal blend shared with three other botanicals, and no individual figure is printed.

That cuts both ways, and both ways are worth stating.

• It makes the safety concern smaller. A fraction of 350 mg shared four ways is a long way below the doses in the risk assessment, and probably a long way below the trial doses too.
• It makes any benefit smaller as well. You cannot have it both ways. If the amount is too small to worry about, it is also too small to do what the trials tested.
• And it makes both unknowable. Without a printed figure, neither statement can be checked. That is the central limitation of a proprietary blend and it applies to every ingredient inside one.

The practical advice is short. If you plan to take a uva-ursi-containing product daily for months rather than weeks, raise it with a clinician, and raise it specifically rather than as a general question about supplements. If you have reduced kidney function, raise it before you start, because the active is cleared renally. And if you are looking at uva-ursi as a way to avoid an antibiotic for an infection you already have, REGATTA is the trial to read first.

Our own safety page carries the same material with the interaction list for the rest of the panel, and the category guide ranks uva-ursi against everything else in the aisle.